Newsroom | 23485 results

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) approved Bixlenvo™ (bictegravir 75 mg/lenacapavir 50 mg), the smallest once-daily single tablet regimen (STR) for the treatment of HIV in adults who are virologically suppressed. Bixlenvo is now the first and only STR option for virologically suppressed people with HIV who are on complex regimens and unable to take currently available STRs. This novel HIV t...

VENLO, Netherlands & HILDEN, Germany--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the commercial launch of QIAsymphony Connect, an IVD-compliant platform for automated clinical nucleic acid extraction. Building on the trusted QIAsymphony platform, with more than 3,300 cumulative placements worldwide, QIAsymphony Connect helps clinical laboratories standardize extraction across diverse assay workflows. The platform delivers highly concentrated DNA and...

MIAMI & LEAWOOD, Kan.--(BUSINESS WIRE)--The American Medical Society for Sports Medicine (AMSSM) and OpenEvidence today announced a partnership that will focus on co-developing AI-powered educational resources on sports medicine for both patients and clinicians. This exclusive collaboration brings the expertise of AMSSM’s sports medicine physicians to OpenEvidence, the leading AI-powered clinical decision support platform, and will build on the AMSSM’s robust foundation of educational materials....

TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health Corporation (Nasdaq: PAHC) (“Phibro” or the “Company”) today announced financial results for its fourth quarter and fiscal year ended June 30, 2026 and provided its financial guidance for the fiscal year ending June 30, 2027. Highlights for the three months ended June 30, 2026 (compared to the three months ended June 30, 2025) – Net sales of $396.7 million, an increase of $18.1 million, or 5% – Net income of $21.7 million, an increase of $4.5...

IRVINE, Calif.--(BUSINESS WIRE)--AIVITA Biomedical, Inc., a biotechnology company developing personalized vaccines for the prevention of infectious disease and treatment of cancer, today announced a new study published in Cell Stem Cell describing a universal, stem cell-derived dendritic cell platform that can be personalized to an individual patient’s tumor and used to train the immune system to attack cancer. The study, “Engineered Human iPSC-Derived Dendritic Cells Dressed with Tumor MHC Com...

LONDRES--(BUSINESS WIRE)--VirTus Respiratory Research Ltd, una organización especializada en investigación por contrato (CRO) en el ámbito respiratorio, fundada por los investigadores del Imperial College de Londres, el profesor Sebastian Johnston y el doctor Michael Edwards, ha destacado hoy su papel en el desarrollo preclínico del APL-10456 de Apollo Therapeutics y el Imperial, tras el anuncio de los datos iniciales positivos del ensayo clínico de fase I de la vacuna. VirTus ha trabajado en e...

LONDEN--(BUSINESS WIRE)--VirTus Respiratory Research Ltd, een CRO (contract research organisation) gespecialiseerd in geneesmiddelen voor de luchtwegen opgericht door professor Sebastian Johnston en Dr. Michael Edwards, onderzoekers van de Imperial College London, belichtte vandaag de rol van de organisatie in de preklinische ontwikkeling van Apollo Therapeutics’ en Imperial’s APL-10456, na de aankondiging van positieve eerste gegevens uit de Fase 1 klinische studie van het vaccin. VirTus werkt...

LONDRA--(BUSINESS WIRE)--VirTus Respiratory Research Ltd, un'organizzazione di ricerca a contratto (CRO) specializzata in patologie respiratorie fondata dal professor Sebastian Johnston e dal Dr. Michael Edwards, ricercatori dell'Imperial College London, oggi ha sottolineato il proprio ruolo nello sviluppo preclinico di APL-10456, di Apollo Therapeutics e dell'Imperial College, a seguito dell'annuncio relativo ai dati iniziali positivi relativi alla fase 1 della sperimentazione clinica sul vacc...

LONDON--(BUSINESS WIRE)--VirTus Respiratory Research Ltd, eine auf Atemwegserkrankungen spezialisierte Auftragsforschungsorganisation (CRO), die von den Forschern Professor Sebastian Johnston und Dr. Michael Edwards vom Imperial College London gegründet wurde, hob heute ihre Rolle bei der präklinischen Entwicklung von APL-10456 von Apollo Therapeutics und dem Imperial College London hervor, nachdem positive erste Daten aus der klinischen Phase-1-Studie des Impfstoffs bekannt gegeben wurden. Vir...

LONDRES--(BUSINESS WIRE)--VirTus Respiratory Research Ltd, une organisation de recherche sous contrat (CRO) spécialisée dans les maladies respiratoires, fondée par le professeur Sebastian Johnston et le docteur Michael Edwards, chercheurs à l’Imperial College de Londres, a souligné aujourd’hui son rôle dans le développement préclinique de l’APL-10456 d’Apollo Therapeutics et de l’Imperial College, à la suite de l’annonce de données initiales positives issues de l’essai clinique de phase 1 du va...